Avantor Results Presentation Deck
Q1 highlights
Strong business momentum
Robust core business growth driven by strengthening market dynamics
Continued COVID-19 tailwinds from vaccine production and diagnostic testing
Significant margin expansion and EPS growth
Ongoing deleveraging; upgrades from 3 credit rating agencies
-
-
Executing on our growth strategy
Announced acquisition of Ritter GmbH to augment our proprietary consumable portfolio
Invested in Biopharma production including global expansions in Single Use capacity
Delivered proprietary innovation:
-
Launched J.T.Baker® BAKERBOND® Resin Chromatography Columns
High-purity silicone materials used in successful NASA Mars Perseverance mission
Looking ahead
Momentum continuing in Q2; strong Biopharma order book
Raising full year outlook for revenue, EBITDA and EPS
avantor™
3View entire presentation